论文部分内容阅读
目的观察阿托伐他汀钙治疗老年急性脑梗死的效果。方法选取2014年7月—2016年1月收治的老年急性脑梗死患者120例,按照随机数表法将其分为观察组和对照组各60例。两组均给予吸氧、抗血小板、抗凝等常规对症治疗。对照组每日睡前口服阿司匹林肠溶片,100 mg/次,1次/d,连续服用7 d后,50 mg/次,1次/d。观察组每日睡前口服阿托伐他汀钙片,20 mg/次,1次/d,连续服用7 d后,10 mg/次,1次/d。两组均持续治疗3个月。对比两组疗效、不良反应发生率,血脂、白细胞介素6(interleukin-6,IL-6)及脑源性神经营养因子(brain-derived neurotrophic factor,BDNF)水平、血管狭窄率。计量资料比较用t检验,计数资料比较采用χ~2检验,P<0.05为差异有统计学意义。结果观察组总有效率、不良反应发生率为(90.00%、5.00%)与对照组(75.00%、15.00%)比较差异有统计学意义(均P<0.05)。治疗后观察组TC、TG、LDL-C、CRP、IL-6及血管狭窄率[(4.20±0.30)、(2.02±0.20)、(2.98±0.33)mmol/L、(7.85±1.20)mg/L、(8.92±2.00)ng/L、(61.14±4.32)%]均低于对照组[(5.35±0.28)、(2.45±0.19)、(3.35±0.40)mmol/L、(10.25±1.45)mg/L、(12.80±1.95)ng/L、(69.57±4.50)%],HDL-C和BDNF[(1.88±0.28)mmol/L、(3.18±0.88)μg/L]高于对照组[(1.49±0.20)mmol/L、(2.64±0.75)μg/L],比较差异有统计学意义(均P<0.05)。结论阿托伐他汀钙可降低老年急性脑梗死患者颈动脉狭窄率,提高BDNF水平,减轻脑损伤。
Objective To observe the effect of atorvastatin calcium on senile acute cerebral infarction. Methods A total of 120 elderly patients with acute cerebral infarction who were admitted from July 2014 to January 2016 were randomly divided into observation group and control group according to the random number table method. Both groups were given oxygen, antiplatelet, anticoagulation and other conventional symptomatic treatment. In the control group, aspirin enteric-coated tablets were orally taken at bedtime before going to bed at a dose of 100 mg once daily for 50 mg once daily for 7 days. Patients in the observation group were given oral atorvastatin calcium 20 mg once daily before going to bed at a dose of 10 mg once daily for 7 days. Both groups continued treatment for 3 months. The curative effect, incidence of adverse reactions, levels of blood lipids, interleukin-6 (IL-6), brain-derived neurotrophic factor (BDNF) and vascular stenosis were compared between the two groups. Comparison of measurement data using t test, count data were compared using χ ~ 2 test, P <0.05 for the difference was statistically significant. Results The total effective rate and the rate of adverse reactions in the observation group were statistically significant (all P <0.05) compared with the control group (75.00%, 15.00%) (90.00%, 5.00%). The levels of TC, TG, LDL-C, CRP and IL-6 in the observation group after treatment were significantly higher than those in the control group (4.20 ± 0.30, 2.02 ± 0.20, 2.98 ± 0.33 mmol / L and 7.85 ± 1.20 mg / L, (8.92 ± 2.00) ng / L, (61.14 ± 4.32)%] were lower than that of the control group [(5.35 ± 0.28), (2.45 ± 0.19), (3.35 ± 0.40) mmol / L, (12.80 ± 1.95) ng / L, (69.57 ± 4.50)%], HDL-C and BDNF [(1.88 ± 0.28) mmol / L and (3.18 ± 0.88) μg / L] (1.49 ± 0.20) mmol / L and (2.64 ± 0.75) μg / L, respectively). The difference was statistically significant (all P <0.05). Conclusions Atorvastatin calcium can reduce carotid stenosis rate, increase BDNF level and reduce brain injury in elderly patients with acute cerebral infarction.